Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could spot colorectal cancer risk from your face, tongue, and breath

NCT ID NCT07815093

Diagnosis Sponsor: Xiuli Zuo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether artificial intelligence can assess colorectal cancer risk by analyzing facial features, tongue images, and exhaled breath. The study enrolls adults aged 18 to 80 who are scheduled for a colonoscopy, collecting their multimodal data before the procedure. The goal is to build a model that could offer a non-invasive alternative to colonoscopy for screening. The study compares the AI model's risk predictions against colonoscopy findings to see if it can accurately detect polyps and cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a non-invasive colorectal cancer risk assessment model built from facial images, tongue images, and exhaled breath data using artificial intelligence
What this could lead to
If it works, this could offer a simple, non-invasive way to flag people at higher risk of colorectal cancer, potentially reducing the need for routine colonoscopy in some cases.
What could go wrong
The approach is unproven and relies on patterns in images and breath that may not reliably distinguish cancer from normal variation. The model could miss cancers or produce false alarms, and it may not perform as well in real-world settings as in this controlled study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 11,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants aged 18-80 years who are scheduled to undergo colonoscopy. All participants provide informed consent. This study enrolls subjects preparing for colonoscopic examination to collect multimodal data for constructing an artificial intelligence-based colorectal cancer risk assessment model.

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18-80 years scheduled to undergo colonoscopy. 2. All patients provide informed consent and sign the informed consent form. Exclusion Criteria: 1. Patients with severe cardiac, cerebral, pulmonary or renal dysfunction, or psychiatric disorders that prevent colonoscopy; 2. Patients with a history of gastrointestinal surgery; 3. Patients taking bismuth agents or other staining medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.